<< Back to Results
LPT 112515 - A Randomized, Phase III, Open-label, Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First or Second Line Trastuzumab plus Chemotherapy in Subjects with HER2 Positive Metastatic Breast Cancer.
Clinical Trial Categories
- The Rosenfeld Cancer Center at 215-481-2402
- The Rosenfeld Cancer Center